New oral cancer drug enters human testing for Tough-to-Treat tumors
NCT ID NCT06625515
Summary
This early-stage study tested a new oral drug called ATX-559 in patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the body processes the drug. Researchers also looked for early signs that the drug might help shrink tumors, especially in cancers with specific genetic features like BRCA mutations or MSI-H/dMMR status.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Stephenson Cancer Center at OU Medicine
Oklahoma City, Oklahoma, 73104, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Colorado Cancer Center - Anschutz Medical Campus,
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.